MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, listed under the ticker HLXA, is a clinical-stage biopharmaceutical company concentrated on inflammatory and autoimmune diseases, with programs spanning dermatology and rheumatology indications. The company accessed public markets through a SPAC business combination and operates within the biotechnology and life sciences sector. On June 9, 2026, MoonLake filed an 8-K current report with the Securities and Exchange Commission under accession number 0001213900-26-066821, signaling a material corporate event requiring public disclosure. The filing reflects continued regulatory reporting activity as the company advances its clinical pipeline. For complete filing breakdowns, sponsor profiles, deal timelines, and real-time SPAC analytics on MoonLake Immunotherapeutics and thousands of other transactions, sign up for full data access at SpacDesk.